Poor N protein antibody in vaccinated, and vaccines lies
Short one.
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Findings Among participants in the mRNA-1273 vaccine efficacy trial with PCR-confirmed Covid-19, anti-nucleocapsid antibody seroconversion at the time of study unblinding (median 53 days post diagnosis and 149 days po…
Keep reading with a 7-day free trial
Subscribe to Things Hidden in Complexity to keep reading this post and get 7 days of free access to the full post archives.